Response rate was observed in 4/11 (36 %) patients with MMP3 or p-IGF1R expression (1 patient was non-evaluable for response) vs 56/78 (71 %) in GIST patients without MMP3 or p-IGF1R expression (2 patients were non-evaluable for response) (p = 0.025). The gene discussed is IGF1R; the disease is gastrointestinal stromal tumor.